Cargando…

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma

Detalles Bibliográficos
Autores principales:	Fecek, Ronald J, Wang, Simeng, Storkus, Walter J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652472/ http://dx.doi.org/10.1186/2051-1426-3-S2-P432

Ejemplares similares

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation
por: Salem, Deepak, et al.
Publicado: (2021)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment
por: Chelvanambi, Manoj, et al.
Publicado: (2021)

Characterization of a the Plasmodium falciparum Hsp70-Hsp90 organising protein
por: Gitau, Grace, et al.
Publicado: (2010)

Potential role of heat shock protein 90 (Hsp90) in HIV uncoating
por: Joshi, Pheroze, et al.
Publicado: (2011)

Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018)

Hsp110 Chaperones Control Client Fate Determination in the Hsp70–Hsp90 Chaperone System
por: Mandal, Atin K., et al.
Publicado: (2010)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

From compound to target: chemical proteomics and in silico screening identify Hsp90 and CDPK2 as putative targets in Plasmodium falciparum
por: Lauciello, Leonardo, et al.
Publicado: (2012)

Role of the Hsp90 cochaperone, FKBPL, in oestrogen receptor signalling and breast cancer growth and survival
por: McKeen, H, et al.
Publicado: (2008)

SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90
por: Lian, Bin, et al.
Publicado: (2021)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
por: Wang, Chun Yan, et al.
Publicado: (2016)

Identification of potential immunotherapeutic targets in antigen presentation and costimulation networks
por: Spaapen, Robbert, et al.
Publicado: (2014)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
por: Smith, Jennifer R., et al.
Publicado: (2008)

The APE2 Exonuclease Is a Client of the Hsp70–Hsp90 Axis in Yeast and Mammalian Cells
por: Omkar, Siddhi, et al.
Publicado: (2022)

Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo
por: Tillotson, Bonnie, et al.
Publicado: (2010)

A switch point in the molecular chaperone Hsp90 responding to client interaction
por: Rutz, Daniel Andreas, et al.
Publicado: (2018)

The Hsp90 isoforms from S. cerevisiae differ in structure, function and client range
por: Girstmair, Hannah, et al.
Publicado: (2019)

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
por: Chesney, Jason, et al.
Publicado: (2018)

Hsp70 Forms Antiparallel Dimers Stabilized by Post-translational Modifications to Position Clients for Transfer to Hsp90
por: Morgner, Nina, et al.
Publicado: (2015)

Transpositional immunity: immunotherapeutical approach against bovine leukemia virus
por: Roa-Castellanos, RA
Publicado: (2009)

Genome-scale Co-evolutionary Inference Identifies Functions and Clients of Bacterial Hsp90
por: Press, Maximilian O., et al.
Publicado: (2013)

HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients
por: Li, Zhaobo, et al.
Publicado: (2017)

ETV6/FLT3 Fusion Is a Novel Client Protein of Hsp90
por: Ly, Bui Thi Kim, et al.
Publicado: (2018)

Client binding shifts the populations of dynamic Hsp90 conformations through an allosteric network
por: Lopez, Abraham, et al.
Publicado: (2021)

Targeting secreted heat shock protein-90alpha (Hsp90α) to prevent breast cancer progression
por: Zhao, Zhengwei, et al.
Publicado: (2010)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

Docking based 3D-QSAR studies applied at the BRAF inhibitors to understand the binding mechanism
por: Mahmood, Uzma, et al.
Publicado: (2012)

The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
por: Guida, Gabriella, et al.
Publicado: (2014)

A novel HSP90 inhibitor, 17-DMAG, induces Tax down-regulation and its oral administration to ATL-model mice intervenes against the infiltration property of the ATL-like lymphocytes and provides extended survival period
por: Ikebe, Emi, et al.
Publicado: (2014)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
por: Gillis, Joanna L., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_raftd9pskt374ttctvb37822lu